News

During this year’s Respiratory Effectiveness Group (REG) Summit (2016 REG Summit), researchers from around the globe highlighted the urgent need for more research into current therapies for chronic obstructive pulmonary disease (COPD). According to a news release, this concern is in line with the announcement by members of the…

GlaxoSmithKline (GSK) recently presented new data from a pre-specified analysis of the SUMMIT clinical trial, showing that once daily treatment with  Breo Ellipta (fluticasone furoate/vilanterol) reduced exacerbations in chronic obstructive pulmonary disease (COPD) patients compared to placebo. The presentation was one of two given at the American Thoracic Society (ATS) 2016 International…

GlaxoSmithKline (GSK) and Innoviva presented positive  results from a Phase 3b study investigating the efficacy and safety of Anoro Ellipta (umeclidinium/vilanterol, or  UMEC/VI) in patients with moderate chronic obstructive pulmonary disease (COPD) who continued to experience symptoms while on tiotropium (bronchodilator) monotherapy. Anoro Ellipta is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting…

AstraZeneca is presenting a broad selection of its novel respiratory disease medicines through more than 60 abstracts and scientific presentations at the American Thoracic Society (ATS) 2016 International Conference through May 18 in San Francisco, Calif. Presentations highlight combinations, respiratory biologics, and scientific research projects that target new pathways…

Sunovion Pharmaceuticals, Inc., will present new clinical and health outcomes data for its Brovana (arformoterol tartrate) Inhalation Solution at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13–18 in San Francisco, California. At the ATS meeting, Sunovion will present post-hoc analyses of clinical data generated from its…

BioScale, Inc. has changed its name to ProterixBio, Inc. to mirror the company’s new strategic path centered on high value clinical applications including disease management services and diagnostics products, according to a May 3 news release. ProterixBio is developing pioneering products to transform chronic disease management. The company will…

AstraZeneca recently announced that its bronchodilator inhalation aerosol medicine Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) has been approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), namely, patients suffering from chronic bronchitis and/or emphysema. Bevespi Aerosphere is the…

Sunovion Pharmaceuticals, Inc., recently reported positive data on its Phase 3 clinical development program for SUN-101 (glycopyrrolate) for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). SUN-101 is dispensed using PARI’s investigational and proprietary nebulizer system, called eFlow. Two 12-week, randomized, double-blind, placebo-controlled and parallel-group, Phase 3 efficacy and safety trials (GOLDEN-3 and…

In the first large-scale study comparing the transcriptomics of a variety of lung diseases, Yale scientists revealed that chronic obstructive pulmonary disease (COPD) shares a network of underlying genes with idiopathic pulmonary fibrosis – another devastating lung disease. The new findings advance our understanding of both conditions, and might possibly…

Researchers at the University of Granada (UGR) and Virgen de las Nieves Hospital in Spain revealed that a brief exercise program, from 7 to 10 days, can improve quality of life and physical abilities while minimizing the need for hospitalization in patients with chronic obstructive pulmonary disease (COPD). The research article, “Results…